Welcome to The CIDP Journey. Join us for a multimedia exploration of where CIDP (chronic inflammatory demyelinating polyneuropathy) treatment and research stands, what the future of care may hold, and the experiences of clinicians and patients as they collaborate on the frontlines of CIDP care.
The CIDP Journey will examine new insights on the importance of accurate and timely diagnosis of CIDP as well as the need to carefully differentiate it from similar disorders.
We will spotlight the collaborative efforts that are enabling patients with CIDP to lead lifestyles consistent with their capabilities. Join us as we examine new medications and other treatment modalities, and address quality-of-life decisions for patients dealing with medication side effects and psychosocial difficulties.
Experience discussions of the role of patient and physician collaboration in sustaining continuity of care and in tailoring therapy to individual patient needs and preferences. And, importantly, view the impact of CIDP through the eyes of individual patients who generously tell their stories of how they build their lives around their abilities, not their disabilities.
The road to a cure for CIDP lies ahead. Along the way, clinicians, physicians, and patients are sharing their stories of working toward that goal at The CIDP Journey. We invite you to join them.
Walk with us.
Zachary Koontz was diagnosed with CIDP as a senior in college at age 22 after nearly 7 years of visiting different types of health care providers, including podiatrists, chiropractors, physical therapists, and back specialists, for symptoms of leg cramps, stumbling, and tripping.
Assessing grip strength may be a viable way to optimize intravenous immune globulin (IVIg) treatments in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), suggests results from the small, prospective, observational GRIPPER study presented at the annual meeting of the American Association for Neuromuscular and Electrodiagnostic Medicine in Austin, Tex.
When a patient presents with polyneuropathy and progressive or relapsing symptoms such as tingling, proximal weakness, and absent reflexes, the clinician should consider a diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP), according to the National Institutes of Health. Confirming the diagnosis requires further testing, however.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is such a remarkably heterogeneous disorder – one with diverse presentations, a highly variable disease course, and differing, often unpredictable treatment responses – that neurologist-researchers around the world have established research registries in recent years to prospectively study patients over time.
CIDP trials pursue treatment biomarkers, but clinical expertise in diagnosis, treatment remains shaky
Chronic inflammatory demyelinating polyneuropathy (CIDP) can be a difficult condition for neurologists to navigate, and yet most clinicians may be failing to follow current standards for diagnosis and treatment, based on a nationwide survey.